An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a standalone therapy for cases of depression that haven’t responded to other options.

The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first standalone therapy for adults suffering from major depressive disorder (MDD) who have not responded adequately to at least two oral antidepressants.

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not responded to at least two oral antidepressants.

The US FDA has approved the first of its kind ketamine-based nasal spray which is supposed to act as a standalone therapy for treatment-resistant depression.

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression, the company said on Tuesday.

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato was approved to treat a major depressive disorder,

A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression in the US.

The Central Intelligence Agency with a "low confidence" has changed its stance and concluded that it's likely the COVI-19 virus was leaked from a Chinese lab before it became a global pandemic five years ago.

People using weed for medical purposes are as likely -- or more -- to become addicted to cannabis as recreational tokers, a new study says.

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, placebo-controlled, phase 4 TRD4005 trial.